Cite
Elevated plasma level of the glycolysis byproduct methylglyoxal on admission is an independent biomarker of mortality in ICU COVID-19 patients.
MLA
Alomar, Fadhel A., et al. “Elevated Plasma Level of the Glycolysis Byproduct Methylglyoxal on Admission Is an Independent Biomarker of Mortality in ICU COVID-19 Patients.” Scientific Reports, vol. 12, no. 1, June 2022, pp. 1–22. EBSCOhost, https://doi.org/10.1038/s41598-022-12751-y.
APA
Alomar, F. A., Alshakhs, M. N., Abohelaika, S., Almarzouk, H. M., Almualim, M., Al-Ali, A. K., Al-Muhanna, F., Alomar, M. F., Alhaddad, M. J., Almulaify, M. S., Alessa, F. S., Alsalman, A. S., Alaswad, A., Bidasee, S. R., Alsaad, H. A., Alali, R. A., AlSheikh, M. H., Akhtar, M. S., Al Mohaini, M., & Alsalman, A. J. (2022). Elevated plasma level of the glycolysis byproduct methylglyoxal on admission is an independent biomarker of mortality in ICU COVID-19 patients. Scientific Reports, 12(1), 1–22. https://doi.org/10.1038/s41598-022-12751-y
Chicago
Alomar, Fadhel A., Marai N. Alshakhs, Salah Abohelaika, Hassan M. Almarzouk, Mohammed Almualim, Amein K. Al-Ali, Fahad Al-Muhanna, et al. 2022. “Elevated Plasma Level of the Glycolysis Byproduct Methylglyoxal on Admission Is an Independent Biomarker of Mortality in ICU COVID-19 Patients.” Scientific Reports 12 (1): 1–22. doi:10.1038/s41598-022-12751-y.